The recent completion of the GLP-1 RA trials using semaglutide4 and the FINEARTS-HF trial evaluating finerenone25 has expanded the therapeutic landscape for patients with heart failure and LVEF up to 40%. This evidence concerns the gene GLP1R and heart failure.